NICE to reassess Kyowa Kirin's Poteligeo pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
NICE uphold appeal by Kyowa Kirin, for POTELIGEO in the treatment of those living with certain ultra-rare blood cancers The National Institute for Health and Care Excellence (NICE) has upheld an appeal
Kyowa Kirin Responds to the National Institute for Health and Care Excellence (NICE) Decision to Not Provide People Living With Certain Rare Blood Cancers Access to POTELIGEO (mogamulizumab)
two very rare forms of non-Hodgkin lymphoma will not have access to
an innovative systemic treatment following NICE s decision to not recommend mogamulizumab for routine use in the NHS
. Kyowa Kirin is disappointed by this decision but remains committed to finding a resolution with NICE.
The National Institute for Health and Care Excellence (NICE) today published its final appraisal document (FAD) for POTELIGEO
(mogamulizumab) announcing that POTELIGEO will not be made available on the NHS